MCID: ETN001
MIFTS: 58

Eating Disorder

Categories: Mental diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Eating Disorder

Summaries for Eating Disorder

MedlinePlus: 41 What are eating disorders? Eating disorders are serious mental health disorders. They involve severe problems with your thoughts about food and your eating behaviors. You may eat much less or much more than you need. Eating disorders are medical conditions; they are not a lifestyle choice. They affect your body's ability to get proper nutrition. This can lead to health issues, such as heart and kidney problems, or sometimes even death. But there are treatments that can help. What are the types of eating disorders? Common types of eating disorders include: Binge-eating, which is out-of-control eating. People with binge-eating disorder keep eating even after they are full. They often eat until they feel very uncomfortable. Afterward, they usually have feelings of guilt, shame, and distress. Eating too much too often can lead to weight gain and obesity. Binge-eating disorder is the most common eating disorder in the U.S. Bulimia nervosa. People with bulimia nervosa also have periods of binge-eating. But afterwards, they purge, by making themselves throw up or using laxatives. They may also over-exercise or fast. People with bulimia nervosa may be slightly underweight, normal weight, or overweight. Anorexia nervosa. People with anorexia nervosa avoid food, severely restrict food, or eat very small quantities of only certain foods. They may see themselves as overweight, even when they are dangerously underweight. Anorexia nervosa is the least common of the three eating disorders, but it is often the most serious. It has the highest death rate of any mental disorder. What causes eating disorders? The exact cause of eating disorders is unknown. Researchers believe that eating disorders are caused by a complex interaction of factors. These include genetic, biological, behavioral, psychological, and social factors. Who is at risk for eating disorders? Anyone can develop an eating disorder, but they are more common in women. Eating disorders frequently appear during the teen years or young adulthood. But people can also develop them during childhood or later in life. What are the symptoms of eating disorders? The symptoms of eating disorders vary, depending on the disorder: The symptoms of binge-eating include: Eating unusually large amounts of food in a specific amount of time, such as a 2-hour period Eating even when you're full or not hungry Eating fast during binge episodes Eating until you're uncomfortably full Eating alone or in secret to avoid embarrassment Feeling distressed, ashamed, or guilty about your eating Frequently dieting, possibly without weight loss The symptoms of bulimia nervosa include the same symptoms as binge-eating, plus trying to get rid of the food or weight after binging by: Purging, making yourself throw up or using laxatives or enemas to speed up the movement of food through your body Doing intensive and excessive exercise Fasting Over time, bulimia nervosa can cause health problems such as: Chronically inflamed and sore throat Swollen salivary glands in the neck and jaw area Worn tooth enamel and increasingly sensitive and decaying teeth. This is caused by the exposure to stomach acid every time you throw up. GERD (acid reflux) and other gastrointestinal problems Severe dehydration from purging Electrolyte imbalance, which could be too low or too high levels of sodium, calcium, potassium and other minerals. This can lead to a stroke or heart attack. The symptoms of anorexia nervosa include: Eating very little, to the point of starving yourself Intensive and excessive exercise Extreme thinness Intense fear of gaining weight Distorted body image - seeing yourself as overweight even when you are severely underweight Over time, anorexia nervosa can cause health problems such as: Thinning of the bones (osteopenia or osteoporosis) Mild anemia Muscle wasting and weakness Thin, brittle hair and nails Dry, blotchy, or yellowish skin Growth of fine hair all over the body Severe constipation Low blood pressure Slowed breathing and pulse Feeling cold all the time because of a drop in internal body temperature Feeling faint, dizzy, or weak Feeling tired all the time Infertility Damage to the structure and function of the heart Brain damage Multiorgan failure Anorexia nervosa can be fatal. Some people with this disorder die of complications from starvation, and others die of suicide. Some people with eating disorders may also have other mental disorders (such as depression or anxiety) or problems with substance use. How is eating disorders diagnosed? Because eating disorders can be so serious, it is important to seek help if you or a loved one thinks that you might have a problem. Your health care provider may use many tools to make a diagnosis: A medical history, which includes asking about your symptoms. It is important to be honest about your eating and exercise behaviors so your provider can help you. A physical exam Blood or urine tests to rule out other possible causes of your symptoms Other tests to see whether you have any other health problems caused by the eating disorder. These can include kidney function tests and an electrocardiogram (EKG or ECG). What are the treatments for eating disorders? Treatment plans for eating disorders are tailored to individual needs. You will likely have a team of providers helping you, including doctors, nutritionists, nurses, and therapists. The treatments may include: Individual, group, and/or family psychotherapy. Individual therapy may include cognitive behavioral approaches, which help you to identify and change negative and unhelpful thoughts. It also helps you build coping skills and change behavioral patterns. Medical care and monitoring, including care for the complications that eating disorders can cause Nutrition counseling. Doctors, nurses, and counselors will help you eat healthy to reach and maintain a healthy weight. Medicines, such as antidepressants, antipsychotics, or mood stabilizers, may help treat some eating disorders. The medicines can also help with the depression and anxiety symptoms that often go along with eating disorders. Some people with serious eating disorders may need to be in a hospital or in a residential treatment program. Residential treatment programs combine housing and treatment services. NIH: National Institute of Mental Health

MalaCards based summary: Eating Disorder, also known as eating disorders, is related to bulimia nervosa and anorexia nervosa, and has symptoms including decrease in appetite, adipsia and symptoms concerning nutrition, metabolism, and development. An important gene associated with Eating Disorder is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are GPCR downstream signalling and Signal Transduction. The drugs Zinc cation and Zinc sulfate have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and kidney, and related phenotypes are Weakly decreased NFAT1-GFP nuclear translocation and homeostasis/metabolism

Disease Ontology: 11 A specific developmental disorder that is characterized by abnormal eating habits that may involve either insufficient or excessive food intake to the detriment of an individual's physical and emotional health.

Wikipedia: 75 An eating disorder is a mental disorder defined by abnormal eating behaviors that negatively affect a... more...

Related Diseases for Eating Disorder

Diseases related to Eating Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 594)
# Related Disease Score Top Affiliating Genes
1 bulimia nervosa 32.4 SLC6A4 SLC6A3 PYY NPY MC4R LEP
2 anorexia nervosa 31.9 SLC6A4 PYY NPY MC4R LEPR LEP
3 personality disorder 31.3 SLC6A4 SLC6A3 OXTR DRD2 CRHR2 COMT
4 alexithymia 31.1 SLC6A4 OXTR DRD2 COMT BDNF ANKK1
5 major depressive disorder 31.1 SLC6A4 SLC6A3 OPRM1 NPY LEP HCRTR1
6 amenorrhea 31.0 PYY NPY LEP GHRL
7 acute stress disorder 31.0 SLC6A4 CRHR2 BDNF
8 type 1 diabetes mellitus 31.0 LEPR LEP GHRL COMT
9 abdominal obesity-metabolic syndrome 1 31.0 LEPR LEP GHRL
10 obsessive-compulsive personality disorder 30.9 SLC6A4 COMT
11 borderline personality disorder 30.9 SLC6A4 SLC6A3 OXTR DRD2 CRHR2 COMT
12 restless legs syndrome 30.9 SLC6A4 SLC6A3 HCRT DRD2 COMT
13 autism spectrum disorder 30.9 SLC6A4 SLC6A3 OXTR LEP GHRL DRD2
14 obsessive-compulsive disorder 30.9 SLC6A4 SLC6A3 OXTR NPY LEP GHRL
15 mood disorder 30.9 SLC6A4 SLC6A3 NPY HCRT DRD2 CRHR2
16 avoidant personality disorder 30.9 SLC6A4 SLC6A3
17 autism 30.8 SLC6A4 SLC6A3 OXTR LEP GHRL DRD2
18 post-traumatic stress disorder 30.8 SLC6A4 SLC6A3 OXTR NPY HCRT DRD2
19 alcohol use disorder 30.8 SLC6A4 SLC6A3 OPRM1 NPY DRD2 COMT
20 nutritional deficiency disease 30.8 PYY NPY LEPR LEP GHRL CCK
21 generalized anxiety disorder 30.8 SLC6A4 DRD2 COMT BDNF
22 leptin deficiency or dysfunction 30.8 PYY NPY MC4R LEPR LEP HCRT
23 bipolar disorder 30.8 SLC6A4 SLC6A3 OPRM1 LEP DRD2 CRHR2
24 dysthymic disorder 30.7 SLC6A4 SLC6A3 HCRT COMT BDNF
25 osteoporosis 30.7 LEPR LEP GHRL FTO COMT CNR1
26 chronic pain 30.7 OPRM1 COMT CNR1 BDNF
27 sleep disorder 30.7 SLC6A4 SLC6A3 NPY LEP HCRTR1 HCRT
28 agoraphobia 30.7 SLC6A4 HCRTR1 COMT BDNF
29 social phobia 30.7 SLC6A4 SLC6A3 OXTR DRD2 COMT CCK
30 apnea, obstructive sleep 30.7 PYY LEP HCRT GHRL BDNF
31 postpartum depression 30.7 SLC6A4 OXTR COMT BDNF
32 adjustment disorder 30.6 SLC6A4 HCRT BDNF
33 intermittent explosive disorder 30.6 SLC6A4 DRD2 COMT
34 disease of mental health 30.6 SLC6A4 SLC6A3 OXTR OPRM1 NPY LEP
35 paine syndrome 30.6 SLC6A4 OPRM1 COMT BDNF
36 polysubstance abuse 30.6 DRD2 COMT CNR1
37 substance abuse 30.6 SLC6A4 SLC6A3 OPRM1 NPY HCRT DRD2
38 anovulation 30.5 LEP GHRL DRD2
39 separation anxiety disorder 30.5 SLC6A4 OXTR COMT BDNF
40 irritable bowel syndrome 30.5 SLC6A4 PYY GHRL CRHR2 COMT CCK
41 fibromyalgia 30.5 SLC6A4 OPRM1 NPY LEP COMT BDNF
42 attention deficit-hyperactivity disorder 30.5 SLC6A4 SLC6A3 OXTR OPRM1 NPY LEP
43 endogenous depression 30.5 SLC6A4 SLC6A3 OXTR DRD2 COMT BDNF
44 hypochondriasis 30.5 SLC6A4 BDNF
45 dissociative disorder 30.5 SLC6A4 COMT BDNF
46 neurotic disorder 30.5 SLC6A4 COMT BDNF
47 congenital central hypoventilation syndrome 30.5 SLC6A4 HCRT BDNF
48 body mass index quantitative trait locus 11 30.5 SLC6A3 PYY NPY MC4R LEPR LEP
49 tic disorder 30.5 SLC6A4 SLC6A3 DRD2 COMT
50 anxiety 30.5 SLC6A4 SLC6A3 OXTR OPRM1 NPY LEP

Comorbidity relations with Eating Disorder via Phenotypic Disease Network (PDN):


Major Depressive Disorder

Graphical network of the top 20 diseases related to Eating Disorder:



Diseases related to Eating Disorder

Symptoms & Phenotypes for Eating Disorder

UMLS symptoms related to Eating Disorder:


decrease in appetite; adipsia; symptoms concerning nutrition, metabolism, and development

GenomeRNAi Phenotypes related to Eating Disorder according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Weakly decreased NFAT1-GFP nuclear translocation GR00359-A 9.02 ANKK1 COMT CRHR2 MC4R SLC6A4

MGI Mouse Phenotypes related to Eating Disorder:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 BDNF CCK CNR1 COMT CRHR2 DRD2
2 nervous system MP:0003631 10.38 BDNF CCK CNR1 COMT DRD2 HCRT
3 normal MP:0002873 10.29 BDNF CNR1 DRD2 GHRL LEPR MC4R
4 growth/size/body region MP:0005378 10.25 BDNF CNR1 DRD2 FTO HCRT LEP
5 behavior/neurological MP:0005386 10.21 BDNF CNR1 COMT CRHR2 DRD2 FTO
6 adipose tissue MP:0005375 10.2 CNR1 CRHR2 DRD2 FTO GHRL LEP
7 endocrine/exocrine gland MP:0005379 10.18 BDNF CCK COMT CRHR2 DRD2 FTO
8 no phenotypic analysis MP:0003012 10.1 BDNF CCK CNR1 DRD2 LEPR MC4R
9 digestive/alimentary MP:0005381 9.97 BDNF CNR1 DRD2 GHRL LEP LEPR
10 reproductive system MP:0005389 9.85 BDNF CNR1 COMT DRD2 LEP LEPR
11 integument MP:0010771 9.32 BDNF CNR1 DRD2 FTO LEP LEPR
12 taste/olfaction MP:0005394 9.26 BDNF CNR1 DRD2 SLC6A3

Drugs & Therapeutics for Eating Disorder

Drugs for Eating Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
2
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
3
Dextroamphetamine Approved, Illicit, Investigational Phase 4 51-64-9, 300-62-9 5826 3007
4
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
7
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
8
Baclofen Approved Phase 4 1134-47-0 2284
9
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
10
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
11
Duloxetine Approved Phase 4 136434-34-9, 116539-59-4 60835
12
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
13
Atomoxetine Approved Phase 4 82248-59-7, 83015-26-3 54841
14
Norepinephrine Approved Phase 4 51-41-2 439260
15
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
16
Cyproheptadine Approved Phase 4 129-03-3 2913
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
18
Raclopride Investigational Phase 4 84225-95-6 5118 3033769
19 Hormones Phase 4
20 Hormone Antagonists Phase 4
21 Analgesics, Opioid Phase 4
22 Acidophilus Phase 4
23 Adrenergic Agents Phase 4
24 Antidepressive Agents Phase 4
25 Serotonin Receptor Agonists Phase 4
26 Sympathomimetics Phase 4
27 Psychotropic Drugs Phase 4
28 Dopamine Antagonists Phase 4
29 Folate Phase 4
30 Vitamins Phase 4
31 Vitamin B9 Phase 4
32 Trace Elements Phase 4
33 Vitamin B Complex Phase 4
34 Hematinics Phase 4
35 Micronutrients Phase 4
36 Anti-Obesity Agents Phase 4
37 Hypoglycemic Agents Phase 4
38 Serotonin 5-HT1 Receptor Agonists Phase 4
39 Lipid Regulating Agents Phase 4
40 GABA Agonists Phase 4
41 Incretins Phase 4
42 Appetite Depressants Phase 4
43 Analgesics Phase 4
44 Antiparkinson Agents Phase 4
45 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
46 Excitatory Amino Acid Antagonists Phase 4
47 Contraceptive Agents Phase 4
48 glucocorticoids Phase 4
49 Contraceptives, Oral, Hormonal Phase 4
50 Contraceptives, Oral Phase 4

Interventional clinical trials:

(show top 50) (show all 579)
# Name Status NCT ID Phase Drugs
1 Effect of Zinc Supplementation on Appetite and Growth of Primary Malnourished Children Unknown status NCT03098810 Phase 4 Zinc sulphate
2 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4 a control group;a probiotic-supplemented group
3 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
4 Folic Acid Supplementation for Improving Homocysteine Levels, Cognitive and Depressive Status in Eating Disorders Completed NCT01493674 Phase 4
5 Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
6 Effectiveness of Psychological Treatments for BED Completed NCT00060762 Phase 4
7 Fluoxetine After Weight Restoration in Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
8 A Double-blind, Placebo-controlled, Cross-over Study Using Baclofen in the Treatment of Rumination Syndrome Completed NCT03113396 Phase 4 Baclofen;Placebo oral capsule
9 A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder. Completed NCT00607789 Phase 4 Duloxetine;Placebo
10 An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity Completed NCT00330655 Phase 4 memantine
11 Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients Completed NCT00327834 Phase 4 atomoxetine
12 Naltrexone: Consummatory Behaviors in Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
13 Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children Completed NCT02187952 Phase 4
14 Evaluation of Splanchnic Oximetry,Doppler Flow Velocimetry in the Superior Mesenteric Artery and Feeding Tolerance in VERY LOW BIRTH WEIGHT IUGR and NON-IUGR Infants Receiving Bolus Versus Continuous Enteral Nutrition Completed NCT01341236 Phase 4
15 Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4 Xenical + behavioral intervention
16 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4 Sibutramine;Placebo
17 The Influence of Appetite-Related Central and Gut Hormones in Modulating Binge Eating Behaviour in Obese and Overweight Healthy Subjects Completed NCT01739049 Phase 4 Liraglutide
18 Solriamfetol in Binge Eating Disorder Recruiting NCT04602936 Phase 4 Solriamfetol;Placebo
19 iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children 9 Months to 9 Years 0 Months of Age Recruiting NCT03815019 Phase 4 Megestrol Acetate
20 Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders Terminated NCT02568007 Phase 4 Cyproheptadine
21 Hydroxyzine Effects on Meal-Related Anxiety in Underweight Adolescents and Young Adults Diagnosed With an Eating Disorder - A Pilot Study Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
22 Feedback Versus no Feedback to Improve Patient Outcome in Group Psychotherapy for Eating Disorders: A Randomised Clinical Trial Unknown status NCT01693237 Phase 2, Phase 3
23 Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration Unknown status NCT01567670 Phase 2, Phase 3 Naloxone;naloxone placebo
24 A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving Completed NCT00481975 Phase 3 rimonabant (SR141716)
25 Effects of Oral Stimulation on Feeding Performance, Length of Hospital Stay and Anthropometric Variables of Preterm Infants Completed NCT03911674 Phase 3
26 Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder Completed NCT00414167 Phase 2, Phase 3 bupropion
27 An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder Completed NCT02684279 Phase 3 Dasotraline
28 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder Completed NCT03107026 Phase 3 dasotraline 4mg;dasotraline 6mg;Placebo
29 Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study Completed NCT03292146 Phase 3 Denosumab 60 MG [Prolia];Placebo Injection;Alendronate 70Mg Tab
30 Deficits in Emotion Regulation Skills as a Maintaining Factor in Binge Eating Disorder Completed NCT03717493 Phase 2, Phase 3
31 A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT02009163 Phase 3 Lisdexamfetamine dimesylate
32 Acamprosate in the Treatment of Binge-Eating Disorder Completed NCT00511940 Phase 2, Phase 3 acamprosate
33 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder Completed NCT00402584 Phase 3 sibutramine
34 A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder Completed NCT02564588 Phase 2, Phase 3 Dasotraline;Placebo
35 Sodium Oxybate in the Treatment of Binge Eating Disorder Completed NCT00514995 Phase 2, Phase 3 Sodium Oxybate
36 Meditation-Based Treatment for Binge Eating Disorder Completed NCT00032760 Phase 2, Phase 3
37 Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity Completed NCT01090713 Phase 3 lisdexamfetamine;Placebo control
38 A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder Completed NCT01657019 Phase 3 Lisdexamfetamine dimesylate
39 Randomized, Double-blind Placebo Controlled Trial With Topiramate for the Treatment of Obese Patients With Binge Eating Disorder Completed NCT00307619 Phase 3 topiramate
40 Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients Completed NCT00221442 Phase 3 Zonegran;sugar pill
41 A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity Completed NCT00210808 Phase 2, Phase 3 topiramate
42 Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity: A Single-Center, Double-Blind, Placebo-Controlled, Flexible-Dose Study in Outpatients Completed NCT00277641 Phase 3 Lamotrigine;placebo
43 Armodafinil in Binge Eating Disorder (BED) Completed NCT01010789 Phase 3 Armodafinil;Matching placebo
44 Diaphragmatic Breathing and Progressive Muscle Relaxation: Behavioral Interventions for Gastrointestinal Rumination Completed NCT01576302 Phase 3
45 The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718509 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
46 The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed NCT01718483 Phase 3 SPD489 (Lisdexamfetamine dimesylate);Placebo
47 Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study Recruiting NCT04779216 Phase 3 Romosozumab Prefilled Syringe;Placebo;Alendronate 70Mg Tab
48 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity Recruiting NCT03926052 Phase 3 Lisdexamfetamine Dimesylate;Placebo
49 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity Recruiting NCT03924193 Phase 3 Lisdexamfetamine Dimesylate
50 Cognitive-Behavioral and Pharmacologic Treatment of Binge-Eating Disorder and Obesity Recruiting NCT03946111 Phase 2, Phase 3 Naltrexone and Bupropion

Search NIH Clinical Center for Eating Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Paroxetine
Paroxetine Hydrochloride
Sertraline
Sertraline Hydrochloride

Cochrane evidence based reviews: feeding and eating disorders

Genetic Tests for Eating Disorder

Anatomical Context for Eating Disorder

Organs/tissues related to Eating Disorder:

MalaCards : Brain, Heart, Kidney, Skin, Prefrontal Cortex, Bone, Cortex

Publications for Eating Disorder

Articles related to Eating Disorder:

(show top 50) (show all 23080)
# Title Authors PMID Year
1
A piece of a puzzle-Patient and psychologist experiences of the Affect School as additional treatment in a Swedish eating disorder unit. 62 41
35901040 2022
2
#Fitmom: an experimental investigation of the effect of social media on body dissatisfaction and eating and physical activity intentions, attitudes, and behaviours among postpartum mothers. 41
36224523 2022
3
Impact of an Intuitive Eating Intervention on Disordered Eating Risk Factors in Female-Identifying Undergraduates: A Randomized Waitlist-Controlled Trial. 41
36231362 2022
4
Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa. 53 62
20339027 2010
5
Correlation of BDNF blood levels with interoceptive awareness and maturity fears in anorexia and bulimia nervosa patients. 53 62
20195875 2010
6
Human serotonin transporter expression during megakaryocytic differentiation of MEG-01 cells. 53 62
20041293 2010
7
The regulatory role of neurotensin on the hypothalamic-anterior pituitary axons: emphasis on the control of thyroid-related functions. 53 62
19878995 2010
8
Role of the ghrelin/obestatin balance in the regulation of neuroendocrine circuits controlling body composition and energy homeostasis. 53 62
19733621 2010
9
The association of catechol-O-methyltransferase genotype with the phenotype of women with eating disorders. 53 62
19852950 2010
10
Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding. 53 62
19763327 2009
11
Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study. 53 62
19801960 2009
12
Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. 53 62
19741568 2009
13
Intracerebroventricular administration of leptin increases anxiety-like behavior in female rats after semi-starvation--implications for anxiety in eating disorders. 53 62
19725430 2009
14
Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders. 53 62
19046818 2009
15
Low serum BDNF and food intake regulation: a possible new explanation of the pathophysiology of eating disorders. 53 62
19152823 2009
16
Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. 53 62
18728162 2008
17
Mice overexpressing the 5-hydroxytryptamine transporter show no alterations in feeding behaviour and increased non-feeding responses to fenfluramine. 53 62
18560807 2008
18
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. 53 62
18508462 2008
19
Vagal and hormonal gut-brain communication: from satiation to satisfaction. 53 62
18402643 2008
20
Serotonin transporter binding in eating disorders. 53 62
18165910 2008
21
Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans. 53 62
18199621 2008
22
Structure and function of ghrelin. 53 62
18193177 2008
23
Ghrelin and feedback systems. 53 62
17983856 2008
24
Hormonal alteration in obese adolescents with eating disorder: effects of multidisciplinary therapy. 53 62
18547953 2008
25
[Cannabinoid system and feeding regulation]. 53 62
18551230 2008
26
Central dysregulations in the control of energy homeostasis and endocrine alterations in anorexia and bulimia nervosa. 53 62
18250619 2007
27
Serotonin transporter binding after recovery from eating disorders. 53 62
17690869 2007
28
Nutrition and fertility. 53 62
18043554 2007
29
Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia. 53 62
17376155 2007
30
Clinical features and physiological response to a test meal in purging disorder and bulimia nervosa. 53 62
17768271 2007
31
Cannabinoids in eating disorders and obesity. 53 62
17952656 2007
32
Variations in the preproghrelin gene correlate with higher body mass index, fat mass, and body dissatisfaction in young Japanese women. 53 62
17616759 2007
33
Roles of leptin and ghrelin in eating disorders? 53 62
17548078 2007
34
[Genetic polymorphism of COMT in mental disorders]. 53 62
18046978 2007
35
Leptin and the cardiovascular system: a review. 53 62
18221108 2007
36
Alterations in the autonomic control of heart rate variability in patients with anorexia or bulimia nervosa: correlations between sympathovagal activity, clinical features, and leptin levels. 53 62
17598965 2007
37
[Some neurological and psychiatric complications of the disorders of the hypothalamo-hypophyseal system]. 53 62
17437948 2007
38
HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. 53 62
17691947 2007
39
The role of leptin in anorexia nervosa: clinical implications. 53 62
17060920 2007
40
Blood levels of brain-derived neurotrophic factor correlate with several psychopathological symptoms in anorexia nervosa patients. 53 62
18337636 2007
41
[Leptin and glucose metabolism in eating disorders]. 53 62
17895538 2007
42
Possible role of preproghrelin gene polymorphisms in susceptibility to bulimia nervosa. 53 62
16921495 2006
43
Association of catecholamine-O-methyltransferase and 5-HTTLPR genotype with eating disorder-related behavior and attitudes in females with eating disorders. 53 62
16969275 2006
44
Effect of two fasting periods of different duration on ghrelin response to a mixed meal. 53 62
17015184 2006
45
Plasma agouti-related protein levels in women with anorexia nervosa. 53 62
16904835 2006
46
Eating, sleeping and rewarding: orexin receptors and their antagonists. 53 62
17002215 2006
47
No change between the serum brain-derived neurotrophic factor in female patients with anorexia nervosa before and after partial weight recovery. 53 62
16753247 2006
48
The role of neurotensin in central nervous system pathophysiology: what is the evidence? 53 62
16862241 2006
49
Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview. 53 62
16632412 2006
50
[Brain-derived neurotrophic factor: from nerve growth factor to modulator of brain plasticity in cognitive processes and psychiatric diseases]. 53 62
16078056 2006

Variations for Eating Disorder

Expression for Eating Disorder

Search GEO for disease gene expression data for Eating Disorder.

Pathways for Eating Disorder

GO Terms for Eating Disorder

Cellular components related to Eating Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.5 CNR1 COMT CRHR2 DRD2 FTO HCRTR1
2 membrane GO:0016021 10.5 CNR1 COMT CRHR2 DRD2 FTO HCRTR1
3 plasma membrane GO:0005886 10.4 CNR1 CRHR2 DRD2 HCRTR1 OPRM1 OXTR
4 plasma membrane GO:0005887 10.4 CNR1 CRHR2 DRD2 HCRTR1 OPRM1 OXTR
5 axon terminus GO:0043679 9.88 SLC6A3 DRD2 CRHR2
6 axon GO:0030424 9.83 SLC6A3 OPRM1 GHRL DRD2 COMT CNR1
7 presynaptic membrane GO:0042734 9.8 SLC6A4 SLC6A3 OPRM1 DRD2 CNR1
8 obsolete integral component of postsynaptic membrane GO:0099055 9.46 DRD2 OPRM1 SLC6A3 SLC6A4
9 obsolete integral component of presynaptic membrane GO:0099056 9.02 SLC6A4 SLC6A3 OPRM1 DRD2 CNR1

Biological processes related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.36 OXTR OPRM1 MC4R HCRTR1 GHRL DRD2
2 signal transduction GO:0007165 10.36 OXTR OPRM1 MC4R LEP HCRTR1 DRD2
3 positive regulation of cytosolic calcium ion concentration GO:0007204 10.19 OXTR OPRM1 HCRT GHRL
4 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 10.16 OPRM1 NPY CNR1
5 positive regulation of synapse assembly GO:0051965 10.15 OXTR GHRL BDNF
6 excitatory postsynaptic potential GO:0060079 10.15 OPRM1 HCRT GHRL DRD2
7 memory GO:0007613 10.13 SLC6A4 OXTR CNR1 BDNF
8 neuropeptide signaling pathway GO:0007218 10.1 HCRT HCRTR1 NPY OPRM1 PYY
9 response to nicotine GO:0035094 10.08 SLC6A3 DRD2 CNR1
10 response to nutrient GO:0007584 10.06 SLC6A4 LEP CNR1
11 positive regulation of multicellular organism growth GO:0040018 10.05 SLC6A3 GHRL DRD2
12 negative regulation of blood pressure GO:0045776 10.04 CNR1 DRD2 NPY
13 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 10.04 MC4R DRD2 CRHR2 CNR1
14 positive regulation of cold-induced thermogenesis GO:0120162 10.02 OXTR LEPR LEP HCRT GHRL
15 temperature homeostasis GO:0001659 9.99 DRD2 FTO HCRT
16 sexual reproduction GO:0019953 9.98 LEPR LEP
17 positive regulation of growth hormone secretion GO:0060124 9.98 GHRL DRD2
18 leptin-mediated signaling pathway GO:0033210 9.97 LEPR LEP
19 response to ethanol GO:0045471 9.97 SLC6A3 OPRM1 LEP DRD2 CNR1
20 behavioral response to ethanol GO:0048149 9.96 DRD2 OPRM1
21 dopamine catabolic process GO:0042420 9.96 SLC6A3 COMT
22 monoamine transport GO:0015844 9.96 SLC6A4 SLC6A3
23 regulation of metabolic process GO:0019222 9.96 MC4R LEP CNR1
24 adenohypophysis development GO:0021984 9.95 SLC6A3 DRD2
25 energy reserve metabolic process GO:0006112 9.95 MC4R LEPR LEP
26 hyaloid vascular plexus regression GO:1990384 9.94 SLC6A3 DRD2
27 sperm ejaculation GO:0042713 9.94 OXTR SLC6A4
28 dopamine uptake involved in synaptic transmission GO:0051583 9.93 DRD2 SLC6A3
29 regulation of bone remodeling GO:0046850 9.93 LEPR LEP
30 response to morphine GO:0043278 9.93 OPRM1 DRD2 CNR1
31 negative regulation of dopamine secretion GO:0033602 9.91 CNR1 DRD2
32 bone growth GO:0098868 9.91 LEP LEPR
33 adult feeding behavior GO:0008343 9.91 NPY LEP GHRL
34 positive regulation of eating behavior GO:1904000 9.89 NPY GHRL
35 regulation of brown fat cell differentiation GO:0090335 9.88 LEP FTO
36 regulation of feeding behavior GO:0060259 9.85 MC4R LEPR CNR1
37 response to cocaine GO:0042220 9.85 CNR1 DRD2 OPRM1 OXTR SLC6A3
38 positive regulation of appetite GO:0032100 9.73 OPRM1 NPY GHRL
39 eating behavior GO:0042755 9.65 OXTR OPRM1 LEP HCRT CCK
40 feeding behavior GO:0007631 9.32 PYY NPY MC4R HCRTR1 HCRT DRD2

Molecular functions related to Eating Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 10.13 CNR1 CRHR2 DRD2 HCRTR1 MC4R NPY
2 hormone activity GO:0005179 9.81 PYY NPY LEP GHRL CCK
3 peptide hormone receptor binding GO:0051428 9.73 LEP CCK
4 monoamine transmembrane transporter activity GO:0008504 9.71 SLC6A4 SLC6A3
5 dopamine binding GO:0035240 9.67 SLC6A3 DRD2
6 neuropeptide Y receptor binding GO:0031841 9.62 PYY NPY
7 neuropeptide hormone activity GO:0005184 9.56 PYY NPY HCRT CCK
8 peptide hormone binding GO:0017046 9.32 OXTR MC4R LEPR HCRTR1 CRHR2

Sources for Eating Disorder

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....